| GB | Glioblastoma |
| PDT | Photodynamic therapy |
| GIC | Glioblastoma initiating cells |
| CNS | Central nervous system |
| 5-ALA | 5-aminolevulinic acid |
| PDD | Photodynamic diagnosis |
| PS | Photosensitizer |
| PFS | Progression-free survival |
| CNA | Copy number alterations |
| cnLOH | Copy neutral loss of heterozygosity |
| RFU | Relative fluorescence units |
| MDM1/2 | Mouse double-minute 1 and 2 |
| GFAP | Glial fibrillary acid protein |
| TUJ1 | Tubulin betta class 3 |
| CD44 | Cluster of differentiation-44 |
| CD133 | Cluster of differentiation-133 |
| MGMT | O6-methylguanine-DNA methyltransferase |
| CDK4/6 | Cyclin-dependent kinase 4 and 6 |
| CDKN2A/B | Cyclin-dependent kinase inhibitor 2A/B |
| CCND2 | Cyclin D2 |
| Rb | Retinoblastoma protein |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| PIK3R | Phosphoinositide-3-kinase regulator |
| PTEN | Phosphatase and tensin homolog |
| EGFR | Epidermal growth factor receptor |
| PDGFR1 | Platelet derived growth factor receptor 1 |
| NF1 | Neurofibromin |
| SOX2 | Sex determining region Y-box 2 |
| LDH | Lactate Dehydrogenase |
| NSG | NOD scid gamma mouse |
| TUNEL | Terminal deoxynucleotidyl transferase dUTP Nick End Labeling assay |
| WHO | World health organization |
| HCB | Hospital Clínic de Barcelona |